MARLBOROUGH, Mass., Jan. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2023, on Wednesday, January 31, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the fourth quarter on January 31 prior to the conference call.
A live webcast and replay of the webcast will be accessible at https://investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. For more information, visit www.bostonscientific.com and connect on Twitter and LinkedIn.
CONTACTS:
Media:
Katie Schur
508-683-5574 (office)
Media Relations
Boston Scientific Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
Lauren Tengler
508-683-4479 (office)
Investor Relations
Boston Scientific Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$88.95 |
Daily Change: | 0.29 0.33 |
Daily Volume: | 13,478,978 |
Market Cap: | US$130.760B |
November 25, 2024 November 15, 2024 November 04, 2024 October 30, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB